The National Center for Advancing Translational Sciences, which is the newest branch of the National Institutes of Health, is partnering with big pharma to give academic researchers access to more than 20 drugs that have passed some safety testing in humans but for some reason have been iced by the drug makers.
In a press release, the agency announced that Pfizer, AstraZeneca, and Eli Lilly will make dozens of their compounds available to researchers who will be able to search for new uses for drugs.
NCATS will back the awkwardly named Discovering New Therapeutic Uses for Existing Molecules with $20 million in 2013. According to the release, the companies will provide researchers with the compounds and related data. The partnerships set up by the program will give academics rights to any intellectual property or publications that come from their work with the compounds while the drug makers will retain ownership of the drugs .
These materials were meant to revolutionize the solar industry. Why hasn’t it happened?
Perovskites are promising, but real-world conditions have held them back.
Why China is still obsessed with disinfecting everything
Most public health bodies dealing with covid have long since moved on from the idea of surface transmission. China’s didn’t—and that helps it control the narrative about the disease’s origins and danger.
Anti-aging drugs are being tested as a way to treat covid
Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.
A quick guide to the most important AI law you’ve never heard of
The European Union is planning new legislation aimed at curbing the worst harms associated with artificial intelligence.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.